Rochester, NY 6/9/2009 2:27:48 AM
Late Afternoon Gainers NASDAQ - Sourced WhisperFromWallStreet.com - Keryx Biopharmaceuticals, Inc.,KERX - Arena Pharmaceuticals, Inc.,ARNA - AtriCure, Inc.,ATRC
Keryx Biopharmaceuticals, Inc. - Arena Pharmaceuticals, Inc. - AtriCure, Inc.
Late Afternoon Gainers NASDAQ - Sourced WhisperFromWallStreet.com - Keryx Biopharmaceuticals, Inc.,KERX - Arena Pharmaceuticals, Inc.,ARNA - AtriCure, Inc.,ATRC
Keryx Biopharmaceuticals, Inc.,KERX
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Its products under development include Zerenex, an oral iron-based compound is in Phase II clinical development for the treatment of hyperphosphatemia in patients with end-stage renal disease in the United States and Japan; and KRX-0401, an oral anti-cancer agent in Phase II clinical development that modulates Akt, and various other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival. Keryx Biopharmaceuticals has strategic alliances with AEterna Zentaris Inc.; Panion & BF Biotech, Inc.; Japan Tobacco Inc.; and Torii Pharmaceutical Co., Ltd. for the manufacture and commercialization of its products.
Last Trade: 1.36
Day's Range: 1.24 - 1.58
52wk Range: 0.09 - 1.45
Volume: 10,582,213
Change: Up 0.28 (25.93%)
---
If you are viewing this press release you are obviously interested in making money in the stock market. In today’s market investors need every tool available. WhisperfromWallStreet.com sends FREE alerts to our subscribers on stocks that we feel are ready to move within hours or days. So far in 2009 we have sent 36 stock alerts to our clients and the average price gain has been 88%. To add additional profits to your portfolio please take a minute and sign up for our free alerts. There is no risk to you and you will see just how accurate we are in our alerts.
Investors sign up for our FREE alerts at http://whisperfromwallstreet.com
---
Arena Pharmaceuticals, Inc.,ARNA
Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company also discovers small molecule drug candidates that target G protein-coupled receptors (GPCRs). Its clinical development programs include lorcaserin in Phase 3 trial program for the treatment of obesity; APD791, an anti-thrombotic drug candidate, which has completed Phase 1a and Phase 1b clinical trials; and APD125 that is in Phase 2b clinical trial for the treatment of insomnia. The company's clinical development programs also include APD597, an oral GPR119 agonist that is in Phase 1 clinical trial for the treatment of type 2 diabetes; APD916 drug candidate, which has completed preclinical development for the treatment of narcolepsy and cataplexy; and APD811, a preclinical drug candidate for the treatment of pulmonary arterial hypertension.
Last Trade: 4.83
Day's Range: 4.10 - 4.92
52wk Range: 2.26 - 7.42
Volume: 13,515,131
Change: Up 0.89 (22.59%)
---
AtriCure, Inc.,ATRC
AtriCure, Inc., a medical device company, engages in the development, manufacture, and sale of cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac tissue. It offers AtriCure Isolator, which consists of an ablation and sensing unit, a compact power generator that delivers bipolar radio-frequency energy; AtriCure switch box, a compact switch box, which provides the technology needed for the dual pulsing electrodes, and ability to connect and toggle between multiple devices, including clamps and multifunctional pen; and Isolator Synergy Bipolar Radio-Frequency Ablation Clamps for open-heart procedures and minimally invasive procedures. The company also provides multifunctional bipolar pen, which enables surgeons to toggle back and forth between temporary pacing, sensing, stimulation, and ablation; and Coolrail linear ablation device, which is designed to allow the physician to create an expanded cardiac ablation lesion set during minimally invasive procedures.
Last Trade: 3.43
Day's Range: 2.70 - 3.60
52wk Range: 1.00 - 11.82
Volume: 274,257
Change: Up 0.64 (22.94%)
---
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com
